0
Akcea Therapeutics, Inc. Banner Image

Akcea Therapeutics, Inc. has reached its limit for free report views

Work for Akcea Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Akcea Therapeutics, Inc.

  • Ticker AKCA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Akcea Therapeutics, Inc. Logo Image
  • 201-500 Employees
  • Based in Cambridge, Massachusetts
Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), is a biopharmaceutical company focused on developing and commercializing medicines to treat patients with serious and rare diseases. Akcea is commercializing TEGSEDI┬« (inotersen) and WAYLIVRA┬« (volanesorsen), as well as advancing a mature pipeline of novel medicines, includingMore AKCEA-APO(a)-LRx, vupanorsen (AKCEA-ANGPTL3-LRx), AKCEA-APOCIII-LRx, and AKCEA-TTR-LRx, with the potential to treat multiple diseases. All six medicines were discovered by Ionis, a leader in antisense therapeutics, and are based on Ionis' proprietary antisense technology. TEGSEDI is approved in the U.S., E.U., Canada and Brazil, and WAYLIVRA is approved in the E.U. Akcea is headquartered in Boston, Massachusetts, and is building the infrastructure to commercialize its medicines globally.
Akcea Therapeutics, Inc.

Most Recent Annual Report

Akcea Therapeutics, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Akcea Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports